28.1 C
New York
Thursday, July 3, 2025

Tag: chairman

newssourcecompanyFORcontentinformation1marketbusiness

BUTLER NATIONAL CORPORATION ANNOUNCES FISCAL YEAR END 2025 FINANCIAL RESULTS

-Record earnings increasing to $0.19 per share -Record operating income of $16.8 million, reflecting a 27% increase from prior year OLATHE, Kan., July 3, 2025 /PRNewswire/...

Adecoagro And Tether To Power Bitcoin Mining With Renewable Energy In Brazil

LUXEMBOURG, July 3, 2025 /PRNewswire/ -- Adecoagro S.A. (NYSE: AGRO) ("Adecoagro" or the "Company"), a leading sustainable production company in South America and Tether...

CYMAT ANNOUNCES INVESTOR WEBINAR FOR MONDAY JULY 7 AT 11 AM

MISSISSAUGA, ON, July 3, 2025 /PRNewswire/ - Cymat Technologies Ltd. (TSXV: CYM) (OTCQB: CYMHF) (the "Company" or "Cymat") is pleased to announce that Michael...

CYMAT ANNOUNCES INVESTOR WEBINAR FOR MONDAY JULY 7 AT 11 AM

MISSISSAUGA, ON, July 3, 2025 /CNW/ - Cymat Technologies Ltd. (TSXV: CYM) (OTCQB: CYMHF) (the "Company" or "Cymat") is pleased to announce that Michael...

NANO Nuclear Announces Platinum Sponsorship and Participation in Panel Discussion at the Defense Strategies Institute’s 7th Annual DoD Energy & Power Summit.

New York, N.Y., July 03, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced that it is the Platinum Sponsor of the upcoming Defense Strategies Institute’s 7th Annual DoD Energy & Power Summit to be held on July 9-10, 2025, at the National Housing Center in Washington, DC.

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma...

Adverse events were generally low-grade, transient, and readily manageable

LiveOne (Nasdaq: LVO) Partners with Synervoz for Voice AI and B2B Growth

LOS ANGELES, July 03, 2025 (GLOBE NEWSWIRE) -- LiveOne (Nasdaq: LVO), an award-winning, creator-first music, entertainment, and technology platform, today announced a strategic partnership with Synervoz Communications, Inc. to co-create new products and experiences that power the next wave of voice in native devices and operating systems. LiveOne and Synervoz will also work together to meet the demands of LiveOne’s growing pipeline of B2B initiatives.

Fangzhou Tops China’s App Store Chart for Healthcare Apps

GUANGZHOU, China, July 3, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, earned the top spot in...

METALEX PLANS DRILLING FOR GOLD AT A1 AND A2 CLAIM BLOCKS IN QUEBEC

KELOWNA, BC, July 3, 2025 /CNW/ - Metalex Ventures Ltd. (TSXV: MTX) (the "Company") is pleased to provide an update on planned drilling at its...

Vistra appoints Kim Jenkins as Group Chief Executive Officer

SINGAPORE, July 3, 2025 /PRNewswire/ -- Vistra, a leading provider of essential business solutions that help organisations to invest and grow efficiently and compliantly...

IPO Bound Pace Digitek Limited Inaugurates BESS Manufacturing Facility in Bidadi, Karnataka

BENGALURU, India, July 3, 2025 /PRNewswire/ -- Pace Digitek Limited (Pace Digitek), an experienced multi-disciplinary solutions provider in the telecom passive infrastructure sector, today...

THE PADDOCK MONTEREY WILL MAKE ITS INAUGURAL DEBUT WITH AN EXCITING LINEUP AND DISTINCT POINT OF VIEW DURING MONTEREY CAR WEEK 2025

MONTEREY, Calif., July 3, 2025 /PRNewswire/ -- Making its official debut this year, The Paddock Monterey is carving out a compelling new space in...

Queen Máxima of the Netherlands Appointed Chair of Global Finance & Technology Network’s International Advisory Board

Agustín Carstens, Former General Manager of the Bank for International Settlements, and Sanjiv Bajaj Chairman of Bajaj Finserv, Also Join the Board SINGAPORE, July 3,...

Jacobio’s IND for Phase I/II Clinical Trial of BET Inhibitor JAB-8263 in Autoimmune Diseases has been Accepted

BEIJING, SHANGHAI and BOSTON, July 2, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that it has submitted the Phase I/II Investigational New Drug (IND)...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsChairman

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers